TEL AVIV, Israel, May 17, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and ...
Discusses Clinical Data and Updated Development Strategy for Darlifarnib June 3, 2026 3:15 PM EDTCompany ParticipantsTroy ...
More flexibility in early-phase development for cell therapies is needed, a panel of US Food and Drug Administration (FDA) ...
OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the appointment of two technology and clinical development leaders to senior roles to significantly strengthen the ...
IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsight The IgE receptor antagonists clinical trial ...
NEW YORK, April 17, 2026--(BUSINESS WIRE)--Volastra Therapeutics, a clinical-stage oncology company pioneering therapies targeting chromosomal instability (CIN), today announced multiple scientific ...
Oversubscribed Series B financing co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with ...
As the FDA formally recognizes real-world evidence as eligible confirmatory evidence for drug approval, sponsors face a growing imperative to build the data infrastructure, organizational alignment, ...
Good afternoon, and thank you for joining us today for BioAge Labs R&D Day. I'm Chris Patil, VP of Media at BioAge. Before we begin, I would like to remind everyone that during this call, we will be ...
Oral, Selective RBM39 Degrader Under Evaluation in Phase 1 Trial; Preclinical Data Support Expansion Potential Across Ewing ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results